Regulation of the Immune Checkpoint Indoleamine 2,3-Dioxygenase Expression by Epstein–Barr Virus
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Regulation of the Immune Checkpoint Indoleamine 2,3-Dioxygenase Expression by Epstein–Barr Virus
Authors
Keywords
-
Journal
Biomolecules
Volume 11, Issue 12, Pages 1792
Publisher
MDPI AG
Online
2021-12-01
DOI
10.3390/biom11121792
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- First-Line Nivolumab Plus Ipilimumab vs Chemotherapy in Advanced Non-Small Cell Lung Cancer With Tumor PD-L1 ≥ 1%: Patient-Reported Outcomes From CheckMate 227 Part 1
- (2021) Martin Reck et al. Journal of Thoracic Oncology
- Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve
- (2021) Kellsye P Fabian et al. Journal for ImmunoTherapy of Cancer
- Next generation of immune checkpoint inhibitors and beyond
- (2021) Julian A. Marin-Acevedo et al. Journal of Hematology & Oncology
- The aryl hydrocarbon receptor suppresses immunity to oral squamous cell carcinoma through immune checkpoint regulation
- (2021) Jessica E. Kenison et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The immunotherapeutic role of indoleamine 2,3‐dioxygenase in head and neck squamous cell carcinoma: A systematic review
- (2021) Daniel J. Lin et al. CLINICAL OTOLARYNGOLOGY
- Expression of PD-L1 in EBV-associated malignancies
- (2021) Xiaoxu Li et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Exosomes-carrying Epstein-Barr virus-encoded small RNA-1 induces indoleamine 2, 3-dioxygenase expression in tumor-infiltrating macrophages of oral squamous-cell carcinomas and suppresses T-cell activity by activating RIG-I/IL-6/TNF-α pathway
- (2021) Ati Burassakarn et al. ORAL ONCOLOGY
- Genomic and Immunologic Correlates of Indoleamine 2,3-Dioxygenase Pathway Expression in Cancer
- (2021) Anshuman Panda et al. Frontiers in Genetics
- Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified
- (2021) Estelle Bourbon et al. Blood Advances
- The prognostic value of IDO expression in solid tumors: a systematic review and meta-analysis
- (2020) Sen Wang et al. BMC CANCER
- Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
- (2020) Raju K. Vaddepally et al. Cancers
- Immunohistochemical Features of Indoleamine 2,3-Dioxygenase (IDO) in Various Types of Lymphoma: A Single Center Experience
- (2020) Mee-seon Kim et al. Diagnostics
- Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial
- (2020) Robert J. Motzer et al. CANCER
- Novel Therapies Boosting T Cell Immunity in Epstein Barr Virus-Associated Nasopharyngeal Carcinoma
- (2020) Sarah Renaud et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Predictive Value of CD8 Expression and FoxP3 Methylation in Nasopharyngeal Carcinoma Patients Treated with Chemoradiotherapy in a Non-endemic Area
- (2020) E. Muraro et al. PATHOLOGY & ONCOLOGY RESEARCH
- EBV renders B cells susceptible to HIV-1 in humanized mice
- (2020) Donal McHugh et al. Life Science Alliance
- LBA48 Clinical efficacy and immunity of combination therapy with nivolumab and IDO/PD-L1 peptide vaccine in patients with metastatic melanoma: A phase I/II trial
- (2020) I-M. Svane et al. ANNALS OF ONCOLOGY
- High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy
- (2019) Devarati Mitra et al. ONCOLOGIST
- Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
- (2019) Georgina V Long et al. LANCET ONCOLOGY
- Latency and lytic replication in Epstein–Barr virus-associated oncogenesis
- (2019) Christian Münz NATURE REVIEWS MICROBIOLOGY
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Global Landscape of EBV-Associated Tumors
- (2019) Claire Shannon-Lowe et al. Frontiers in Oncology
- Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
- (2019) Shuang Qin et al. Molecular Cancer
- The silencing of indoleamine 2,3-dioxygenase 1 (IDO1) in dendritic cells by siRNA-loaded lipid nanoparticles enhances cell-based cancer immunotherapy
- (2019) Rikito Endo et al. Scientific Reports
- Development and validation of an immune checkpoint-based signature to predict prognosis in nasopharyngeal carcinoma using computational pathology analysis
- (2019) Ya-Qin Wang et al. Journal for ImmunoTherapy of Cancer
- Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis
- (2019) Catherine de Martel et al. Lancet Global Health
- Are EBV-related and EBV-unrelated Hodgkin lymphomas different with regard to susceptibility to checkpoint blockade?
- (2018) Antonino Carbone et al. BLOOD
- Tumor-Repopulating Cells Induce PD-1 Expression in CD8 + T Cells by Transferring Kynurenine and AhR Activation
- (2018) Yuying Liu et al. CANCER CELL
- Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
- (2018) Kristian M. Hargadon et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Reversal of indoleamine 2,3-dioxygenase–mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme
- (2018) Todd A Triplett et al. NATURE BIOTECHNOLOGY
- Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
- (2018) Seung Tae Kim et al. NATURE MEDICINE
- A new cancer immunotherapy suffers a setback
- (2018) Ken Garber SCIENCE
- Epstein‑Barr virus‑encoded microRNA BART7 downregulates major histocompatibility complex class I chain‑related peptide A and reduces the cytotoxicity of natural killer cells to nasopharyngeal carcinoma
- (2018) Thian‑Sze Wong et al. Oncology Letters
- Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas
- (2018) Seok-Jin Kim et al. Cancer Research and Treatment
- A Landscape of Metabolic Variation across Tumor Types
- (2018) Ed Reznik et al. Cell Systems
- Ephrin receptor A2 is an epithelial cell receptor for Epstein–Barr virus entry
- (2018) Hua Zhang et al. Nature Microbiology
- Ephrin receptor A2 is a functional entry receptor for Epstein–Barr virus
- (2018) Jia Chen et al. Nature Microbiology
- Epstein–Barr Virus and Cancer
- (2018) Paul J. Farrell Annual Review of Pathology-Mechanisms of Disease
- Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
- (2018) Tara C. Mitchell et al. JOURNAL OF CLINICAL ONCOLOGY
- Epacadostat plus nivolumab for advanced melanoma: Updated phase 2 results of the ECHO-204 study.
- (2018) Adil Daud et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 trial of the IDO pathway inhibitor indoximod plus checkpoint inhibition for the treatment of patients with advanced melanoma.
- (2018) Yousef Zakharia et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the IDO1 pathway in cancer: from bench to bedside
- (2018) Ming Liu et al. Journal of Hematology & Oncology
- Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
- (2018) Bruno Gomes et al. MOLECULAR CANCER THERAPEUTICS
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- EBV MicroRNA BART16 Suppresses Type I IFN Signaling
- (2017) Marjolein J. G. Hooykaas et al. JOURNAL OF IMMUNOLOGY
- Epstein-Barr Virus miR-BART6-3p Inhibits the RIG-I Pathway
- (2017) Yuanjun Lu et al. Journal of Innate Immunity
- Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer
- (2017) Anshuman Panda et al. JNCI-Journal of the National Cancer Institute
- De-novo and acquired resistance to immune checkpoint targeting
- (2017) Nicholas L Syn et al. LANCET ONCOLOGY
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pretreatment Epstein-Barr virus DNA in whole blood is a prognostic marker in peripheral T-cell lymphoma
- (2017) Yu Ri Kim et al. Oncotarget
- Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer
- (2017) Anshuman Panda et al. JNCI-Journal of the National Cancer Institute
- Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance
- (2017) Marc Hennequart et al. Cancer Immunology Research
- An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma
- (2016) Hasita Horlad et al. CANCER SCIENCE
- Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients
- (2016) C. Laurent et al. HAEMATOLOGICA
- Prognostic value of indoleamine 2,3-dioxygenase activity and expression in nasopharyngeal carcinoma
- (2016) Ahlem Ben-Haj-Ayed et al. IMMUNOLOGY LETTERS
- Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges
- (2016) Chrisann Kyi et al. Immunotherapy
- PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
- (2016) Margaretha G.M. Roemer et al. JOURNAL OF CLINICAL ONCOLOGY
- Concordance of immune checkpoints within tumor immune contexture and their prognostic significance in gastric cancer
- (2016) Congqi Dai et al. Molecular Oncology
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
- (2016) Celine Boutros et al. Nature Reviews Clinical Oncology
- PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
- (2016) Aaron Goodman et al. Nature Reviews Clinical Oncology
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers
- (2016) Sarah Derks et al. Oncotarget
- Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients
- (2016) C. Laurent et al. HAEMATOLOGICA
- Tolerogenic IDO+ Dendritic Cells Are Induced by PD-1-Expressing Mast Cells
- (2016) Cecilia Pessoa Rodrigues et al. Frontiers in Immunology
- Increased expression of IDO associates with poor postoperative clinical outcome of patients with gastric adenocarcinoma
- (2016) Hao Liu et al. Scientific Reports
- EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment
- (2015) A. Nicolae et al. BLOOD
- Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab
- (2015) Zeynep Eroglu et al. EUROPEAN JOURNAL OF CANCER
- 511 Updated results from a phase 1/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma
- (2015) G. Gibney et al. EUROPEAN JOURNAL OF CANCER
- Indoleamine 2,3-dioxygenase depletes tryptophan, activates general control non-derepressible 2 kinase and down-regulates key enzymes involved in fatty acid synthesis in primary human CD4+T cells
- (2015) Theodoros Eleftheriadis et al. IMMUNOLOGY
- B-Cells induce regulatory T cells through TGF-β/IDO production in A CTLA-4 dependent manner
- (2015) A. Nouël et al. JOURNAL OF AUTOIMMUNITY
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro
- (2015) Lina Quan et al. PLoS One
- RIG-I in RNA virus recognition
- (2015) Alison M. Kell et al. VIROLOGY
- IL-27 induces the expression of IDO and PD-L1 in human cancer cells
- (2015) Grazia Carbotti et al. Oncotarget
- Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: a retrospective cohort study
- (2014) Ji-Young Choe et al. BMC CANCER
- IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation
- (2014) Richard Metz et al. INTERNATIONAL IMMUNOLOGY
- Epstein-Barr Virus Infection Induces Indoleamine 2,3-Dioxygenase Expression in Human Monocyte-Derived Macrophages through p38/Mitogen-Activated Protein Kinase and NF- B Pathways: Impairment in T Cell Functions
- (2014) W.-l. Liu et al. JOURNAL OF VIROLOGY
- Aryl hydrocarbon receptor control of a disease tolerance defence pathway
- (2014) Alban Bessede et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Global burden of deaths from Epstein-Barr virus attributable malignancies 1990-2010
- (2014) Gulfaraz Khan et al. Infectious Agents and Cancer
- Tryptophan-Catabolizing Enzymes – Party of Three
- (2014) Helen J. Ball et al. Frontiers in Immunology
- Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
- (2014) Stefani Spranger et al. Journal for ImmunoTherapy of Cancer
- Gene Expression Profiling Reveals Clear Differences Between EBV-Positive and EBV-Negative Posttransplant Lymphoproliferative Disorders
- (2013) J. Morscio et al. AMERICAN JOURNAL OF TRANSPLANTATION
- PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
- (2013) B. J. Chen et al. CLINICAL CANCER RESEARCH
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- (2013) S. Spranger et al. Science Translational Medicine
- A structure-based model of RIG-I activation
- (2012) D. Kolakofsky et al. RNA
- IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan
- (2012) Richard Metz et al. OncoImmunology
- Identification of Epstein-Barr Virus-Induced Gene 3 as a Novel Serum and Tissue Biomarker and a Therapeutic Target for Lung Cancer
- (2011) R. Nishino et al. CLINICAL CANCER RESEARCH
- IDO metabolite produced by EBV-transformed B cells inhibits surface expression of NKG2D in NK cells via the c-Jun N-terminal kinase (JNK) pathway
- (2011) Hyunkeun Song et al. IMMUNOLOGY LETTERS
- Epstein-Barr Virus-Induced Gene 3 (EBI3): A Novel Diagnosis Marker in Burkitt Lymphoma and Diffuse Large B-Cell Lymphoma
- (2011) Julie Gonin et al. PLoS One
- Inhibition of NKG2D expression in NK cells by cytokines secreted in response to human cytomegalovirus infection
- (2010) A. Muntasell et al. BLOOD
- An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells
- (2010) J. D. Mezrich et al. JOURNAL OF IMMUNOLOGY
- Crystal structure of the Epstein-Barr virus (EBV) glycoprotein H/glycoprotein L (gH/gL) complex
- (2010) H. Matsuura et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment
- (2009) H. Harlin et al. CANCER RESEARCH
- IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism
- (2008) Stefan Löb et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase
- (2008) A. J. Muller et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immune escape by Epstein–Barr virus associated malignancies
- (2008) Christian Münz et al. SEMINARS IN CANCER BIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now